MDT vs. GILD, ELV, SYK, SNY, ISRG, VRTX, REGN, AMGN, ZTS, and MRNA
Should you be buying Medtronic stock or one of its competitors? The main competitors of Medtronic include Gilead Sciences (GILD), Elevance Health (ELV), Stryker (SYK), Sanofi (SNY), Intuitive Surgical (ISRG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Amgen (AMGN), Zoetis (ZTS), and Moderna (MRNA). These companies are all part of the "medical" sector.
Medtronic vs.
Gilead Sciences (NASDAQ:GILD) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.
Gilead Sciences has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500.
Medtronic has a net margin of 14.03% compared to Gilead Sciences' net margin of 12.29%. Gilead Sciences' return on equity of 38.51% beat Medtronic's return on equity.
Gilead Sciences has higher earnings, but lower revenue than Medtronic. Medtronic is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.
Gilead Sciences received 868 more outperform votes than Medtronic when rated by MarketBeat users. Likewise, 78.07% of users gave Gilead Sciences an outperform vote while only 77.22% of users gave Medtronic an outperform vote.
Gilead Sciences presently has a consensus target price of $87.40, indicating a potential upside of 4.38%. Medtronic has a consensus target price of $94.25, indicating a potential upside of 14.13%. Given Medtronic's higher probable upside, analysts plainly believe Medtronic is more favorable than Gilead Sciences.
78.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 80.4% of Medtronic shares are owned by institutional investors. 0.2% of Gilead Sciences shares are owned by company insiders. Comparatively, 0.3% of Medtronic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Gilead Sciences pays an annual dividend of $2.92 per share and has a dividend yield of 3.5%. Medtronic pays an annual dividend of $2.72 per share and has a dividend yield of 3.3%. Gilead Sciences pays out 110.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Medtronic pays out 84.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences has raised its dividend for 7 consecutive years and Medtronic has raised its dividend for 46 consecutive years.
In the previous week, Gilead Sciences had 18 more articles in the media than Medtronic. MarketBeat recorded 24 mentions for Gilead Sciences and 6 mentions for Medtronic. Gilead Sciences' average media sentiment score of 0.65 beat Medtronic's score of -0.20 indicating that Gilead Sciences is being referred to more favorably in the media.
Summary
Gilead Sciences beats Medtronic on 12 of the 21 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Medtronic Competitors List
